Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Mol Cancer Res. 2023 Sep 1;21(9):867–880. doi: 10.1158/1541-7786.MCR-22-1031

Figure 4. ERK1/2 inhibition can block an invasive phenotype in BRAFi-resistant cell lines.

Figure 4.

A) Cells were treated with vehicle, BRAFi, ERKi, or the combination and secreted FN1 was quantified using ELISA assays B) Indicated cells were treated with BRAFi, ERKi, FN1, or the indicated combinations for 24 hrs then plated in Matrigel-coated Boyden chambers for 24 hrs. Invading cells were stained with DAPI and counted using ImageJ or the Cytation 5 Cell Imaging Multi-Mode Reader. Results displayed as mean +/− SEM. *, p<0.05; **, p<0.01. BRAFi: 100 nM dabrafenib, ERKi: 1 μM SCH772984, FN1: 100 ng/ml fibronectin.